RUNX2 and Familial prostate cancer: Gupta and coworkers demonstrated that Integrin αvβ3 and CD44 are involved in prostate cancer patients bone loss by promoting osteoclastogenesis through the RUNX2/Smad 5/receptor activator of NF-κB ligand pathways [43].